^
Association details:
Biomarker:RET fusion
Cancer:Pancreatic Cancer
Drug:Gavreto (pralsetinib) (RET inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Non Small Cell Lung Cancer)
New
Excerpt:
GAVRETO is a kinase inhibitor indicated for treatment of:...Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Published date:
08/12/2022
Excerpt:
...here we present interim data on the efficacy and safety of pralsetinib in prospectively identified patients with diverse RET fusion–positive tumors....Confirmed tumor responses were observed in all four patients with pancreatic cancer (including one CR), two of three patients with cholangiocarcinoma, two of three patients with sarcoma (including one CR), two of three patients with neuroendocrine cancer and single patients with head and neck cancer and unknown primary tumor (CR).
DOI:
https://doi.org/10.1038/s41591-022-01931-y
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.

Published date:
05/19/2021
Excerpt:
 Here we provide an update on the clinical activity of pralsetinib in patients (pts) with advanced RET fusion-positive solid tumors other than NSCLC and thyroid cancer (“other”RET fusion–positive solid tumors)….Responses occurred across multiple tumor types including 3/3 pts with pancreatic cancer (including a CR ongoing at 20.8 months on treatment)...
DOI:
10.1200/JCO.2021.39.15_suppl.3079
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion–positive solid tumors.

Published date:
01/11/2021
Excerpt:
Here, we present data on the clinical activity of pralsetinib in patients with RET fusion–positive solid tumor types....ORR (investigator’s assessment) was 50% (6/12; 95% CI: 21-79) and responses were observed in all patients with pancreatic cancer (3/3)...
DOI:
10.1200/JCO.2021.39.3_suppl.467
Trial ID: